Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND)

What is REWIND?

The REWIND study aims to see whether the investigational drug, dulaglutide, can safely reduce the development of serious heart disease or stroke in people with type 2 diabetes who are at high risk for these conditions.

This study is currently following participants.

Principal Investigator

Elizabeth Seaquist, MD


For More Information

Mike Mech, RN
mechx003@umn.edu
612-624-6697